Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study
- PMID: 28379314
- DOI: 10.1093/cid/cix287
Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study
Abstract
Background: To treat patients with methicillin-susceptible Staphylococcus aureus (MSSA) infections, β-lactams are recommended for definitive therapy; however, the comparative effectiveness of individual β-lactams is unknown. This study compared definitive therapy with cefazolin vs nafcillin or oxacillin among patients with MSSA infections complicated by bacteremia.
Methods: This retrospective study included patients admitted to 119 Veterans Affairs hospitals from 2003 to 2010. Patients were included if they had a blood culture positive for MSSA and received definitive therapy with cefazolin, nafcillin, or oxacillin. Cox proportional hazards regression and ordinal logistic regression were used to identify associations between antibiotic therapy and mortality or recurrence. A recurrent infection was defined as a MSSA blood culture between 45 and 365 days after the first MSSA blood culture.
Results: Of 3167 patients, 1163 (37%) patients received definitive therapy with cefazolin. Patients who received cefazolin had a 37% reduction in 30-day mortality (hazard ratio [HR], 0.63; 95% confidence interval [CI], .51-.78) and a 23% reduction in 90-day mortality (HR, 0.77; 95% CI, .66-.90) compared with patients receiving nafcillin or oxacillin, after controlling for other factors. The odds of recurrence (odds ratio, 1.13; 95% CI, .94-1.36) were similar among patients who received cefazolin compared with patients who received nafcillin or oxacillin, after controlling for other factors.
Conclusions: In this large, multicenter study, patients who received cefazolin had a lower risk of mortality and similar odds of recurrent infections compared with nafcillin or oxacillin for MSSA infections complicated by bacteremia. Physicians might consider definitive therapy with cefazolin for these infections.
Keywords: MSSA; bacteremia; cefazolin; nafcillin; treatment.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Comment in
-
Definitive Treatment for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Data Versus a Definitive Answer?Clin Infect Dis. 2017 Jul 1;65(1):107-109. doi: 10.1093/cid/cix288. Clin Infect Dis. 2017. PMID: 28379366 No abstract available.
-
Economic Impact of a Preferred Anti-Methicillin Susceptible Staphylococcus aureus Protocol.Clin Infect Dis. 2018 Apr 17;66(9):1483-1484. doi: 10.1093/cid/cix1072. Clin Infect Dis. 2018. PMID: 29211820 No abstract available.
Similar articles
-
Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.BMC Infect Dis. 2011 Oct 19;11:279. doi: 10.1186/1471-2334-11-279. BMC Infect Dis. 2011. PMID: 22011388 Free PMC article.
-
Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible Staphylococcus aureus Bloodstream Infection.Open Forum Infect Dis. 2019 Jun 6;6(7):ofz270. doi: 10.1093/ofid/ofz270. eCollection 2019 Jul. Open Forum Infect Dis. 2019. PMID: 31281864 Free PMC article.
-
Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia.Am J Med Sci. 2020 Jul;360(1):35-41. doi: 10.1016/j.amjms.2020.04.006. Epub 2020 Apr 17. Am J Med Sci. 2020. PMID: 32376001
-
The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.Clin Infect Dis. 2013 Dec;57(12):1760-5. doi: 10.1093/cid/cit560. Epub 2013 Aug 28. Clin Infect Dis. 2013. PMID: 23985343 Review.
-
β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.Pharmacotherapy. 2017 Mar;37(3):346-360. doi: 10.1002/phar.1892. Epub 2017 Feb 7. Pharmacotherapy. 2017. PMID: 28035690 Review.
Cited by
-
Evolution of haemostatic parameters and risk of bleeding during treatment with cefazolin.Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):177-183. doi: 10.1007/s10096-018-3412-6. Epub 2018 Nov 10. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30414092
-
Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial.BMJ Open. 2018 Sep 1;8(8):e023151. doi: 10.1136/bmjopen-2018-023151. BMJ Open. 2018. PMID: 30173161 Free PMC article. Clinical Trial.
-
Influence of Reported Penicillin Allergy on Mortality in MSSA Bacteremia.Open Forum Infect Dis. 2018 Feb 19;5(3):ofy042. doi: 10.1093/ofid/ofy042. eCollection 2018 Mar. Open Forum Infect Dis. 2018. PMID: 29594180 Free PMC article.
-
Specialty Grand Challenge In Pediatric Infectious Diseases.Front Pediatr. 2017 Aug 28;5:185. doi: 10.3389/fped.2017.00185. eCollection 2017. Front Pediatr. 2017. PMID: 28894730 Free PMC article. No abstract available.
-
Antimicrobial Resistance and Mortality in Hospitalized Patients with Bacteremia in the Greater Paris Area from 2016 to 2019.Clin Epidemiol. 2022 Dec 14;14:1547-1560. doi: 10.2147/CLEP.S385555. eCollection 2022. Clin Epidemiol. 2022. PMID: 36540898 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical